Safety, Tolerability and Immunogenicity of Gam-COVID-Vac Vaccine in a Nasal Spray

COVID-19 Clinical Trial

— SPRAY  

Official title:

A Randomized Double-blind Placebo-controlled Multi-center Clinical Trial in Parallel Assignment of Safety, Tolerability and Immunogenicity of a Vaccine "Gam-COVID-Vac, a Combined Vector Vaccine for the Prevention of Coronavirus Infection Caused by the SARS-CoV-2 Virus" in a Nasal Spray Dosage Form With the Participation of Adult Volunteers

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05248373
• Other study ID #: SPRAY vaccine against COVID-19
• Status: Not yet recruiting
• Phase: Phase 1/Phase 2
• Start date: March 8, 2022
• Est. completion date: December 30, 2023

Study information

• Verified date: March 2022
• Source: Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
• Contact: Nadezhda L Lubenec
• Phone: 8 (499) 193-30-01
• Email: info[@]gamaleya.org
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Randomized, double-blind, placebo-controlled trial to evaluate safety and immunogenicity of intranasal "Gam-COVID-Vak" combined vector vaccine for the prevention of coronavirus infection caused by the SARS-CoV-2 virus.

The duration of participation in the study for one subject will be 180±14 days after the first dose of vaccine, during which each subject will undergo a screening visit (within a week) and face-to-face visits according to the study plan. Intranasal vaccine administration will be done at day 1 vaccination visits and day 21±2 days on an outpatient basis.

During the follow-up visits key vital signs will be assessed, and will collect data on changes in the state and well-being subjects from a previous visit. Subject data will be collected using electronic forms of individual registration cards, as well as with using questionnaires (diaries) filled by the subjects of the study.

Immunogenicity will be assessed on day 1, 10, 28, 42 and 90 days. Humoral and cellular immune response will be evaluated.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 400
• Est. completion date: December 30, 2023
• Est. primary completion date: February 14, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. The presence of a written informed consent of the subject to participate in the study;

2. Adult volunteers over 18;

3. Negative test result for HIV, hepatitis, syphilis;

4. Negative test result for COVID-2019, determined by PCR at the visit screening, and, if available, the result of the examination performed in medical organizations that are research centers 7 days before inclusion into research;

5. The result of the study for the presence of IgG antibodies to SARS CoV2 up to 10 VGR, which corresponds to value up to 100 BAU, regardless of the immune status before;

6. Absence of contact of the research subject with patients with COVID-2019 for at least 14 days before enrollment in the study (according to the study participant);

7. Consent to use effective methods of contraception during the entire period of participation in research;

8. Negative Urine Pregnancy Test at Screening Visit (for women of childbearing age);

9. Negative test for the presence of narcotic and psychostimulant drugs in the urine for screening visit;

10. Negative alcohol test at screening visit;

11. No history of severe post-vaccination reactions or post-vaccination complications after the use of immunobiological preparations;

12. Absence of acute infectious and/or respiratory diseases for at least within 14 days prior to enrollment in the study.

Exclusion Criteria:

1. Inability to give informed consent, inability to understand the essence of the study

2. Any vaccination/immunization carried out within 30 days prior to inclusion in study;

3. Steroid therapy (excluding hormonal contraceptives) and/or immunoglobulins or other blood products, not completed 30 days before inclusion in the study;

4. COVID-2019 disease or vaccination to prevent COVID-2019 in less than six months before inclusion in the study

5. Immunosuppressive drug therapy completed less than 3 months before inclusion in the study;

6. Postponed less than one year prior to enrollment in the study acute coronary syndrome or stroke;

7. Tuberculosis, chronic systemic infections;

8. Exacerbation of rhinitis

9. Burdened allergic history (presence in the anamnesis of information about anaphylactic shock, angioedema, polymorphic exudative eczema, serum sickness), hypersensitivity or allergic reactions to the introduction of immunobiological drugs, known allergic reactions to drug components, exacerbation allergic diseases on the day of inclusion in the study;

10. History of neoplasms (ICD codes C00-D09);

11. Donation of blood or plasma (in a volume of 450 ml or more) less than 2 months before inclusion in the study;

12. Splenectomy in history;

13. Neutropenia (decrease in the absolute number of neutrophils less than 1000/mm3), agranulocytosis, significant blood loss, severe anemia (hemoglobin less than 80 g/l), immunodeficiency in history within 6 months prior to enrollment in the study;

14. Subjects with active human immunodeficiency virus disease syphilis, hepatitis B and C;

15. Anorexia, protein deficiency of any origin;

16. History of alcoholism and drug addiction;

17. Participation of the subject in any other interventional clinical trial during this study;

18. Any other condition of the research subject that, in the opinion of the research physician, may prevent completion of the study in accordance with the protocol;

19. Staff of research centers and other staff directly involved in conducting the study (principal investigator and members of the research team) and members of their families.

Related Conditions & MeSH terms

• COVID-19
• Respiration Disorders
• Respiratory Tract Diseases
• SARS-CoV-2 Acute Respiratory Disease

Intervention

Biological:
• Gam-COVID-Vac
two-component combined vector vaccine for the prevention of coronavirus infection caused by the SARS-CoV-2 virus

Other:
• Placebo
solution with same composition as for vaccine formulation except rAds

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change from baseline in geometric mean titer of IgGs specific to S protein	Change from baseline in Geometric mean titer of IgGs specific to S protein at different time points after vaccination	0, 10, 28, 42, 90 day
Primary	Change from baseline in number of participants with detected specific IgGs	Change from baseline in Number of participants with detected specific IgGs at different time points after vaccination	0, 10, 28, 42, 90 day
Primary	Change from baseline in Number of participants with detected specific IgAs	Change from baseline in Number of participants with detected specific IgAs at different time points after vaccination	0, 10, 28, 42 day
Primary	Change from baseline in Geometric mean titer of neutralizing antibodies to SARS-Cov-2 virus	Change from baseline in Geometric mean titer of neutralizing antibodies to SARS-Cov-2 virus at different time points after vaccination	0, 28, 42, 90 day
Primary	Change from baseline in Number of participants with detected neutralizing antibodies to SARS-Cov-2 virus	Change from baseline in Number of participants with detected neutralizing antibodies to SARS-Cov-2 virus at different time points after vaccination	0, 28, 42, 90 day
Primary	Proportion of participants with any adverse events	AEs evaluation during the whole period of the study	1-180 days
Primary	Proportion of participants with severe adverse events	SAEs evaluation during the whole period of the study	1-180 days
Secondary	Efficacy of symptomatic COVID-19 prevention	Efficacy of symptomatic COVID-19 prevention	28-180 days